GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood… Read more
GenixPharmaceucticals Corporation (GENX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of April 2025: 0.011x
Based on the latest financial reports, GenixPharmaceucticals Corporation (GENX) has a cash flow conversion efficiency ratio of 0.011x as of April 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-14.24K) by net assets (CA$-1.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GenixPharmaceucticals Corporation - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how GenixPharmaceucticals Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GenixPharmaceucticals Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenixPharmaceucticals Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greenlit Ventures Inc
PINK:GLVT
|
N/A |
|
Sprott Physical Gold and Silver Trust
TO:CEF
|
-0.001x |
|
Tangiamo Touch Technology AB
ST:TANGI
|
0.021x |
|
BARNES GROUP
BE:BG4
|
0.036x |
|
EGRNF
PINK:EGRNF
|
-0.527x |
|
James Bay Resources Limited
PINK:JMBRF
|
0.145x |
|
Community Redevelopment Inc
PINK:CRDV
|
N/A |
|
PSI F.PR.U.SYS N
MU:PSAN
|
-0.375x |
Annual Cash Flow Conversion Efficiency for GenixPharmaceucticals Corporation (2015–2024)
The table below shows the annual cash flow conversion efficiency of GenixPharmaceucticals Corporation from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-10-31 | CA$-1.18 Million | CA$-187.34K | 0.158x | -18.39% |
| 2023-10-31 | CA$-1.14 Million | CA$-220.67K | 0.194x | +382.67% |
| 2022-10-31 | CA$3.20 Million | CA$-219.58K | -0.069x | +35.67% |
| 2021-10-31 | CA$4.01 Million | CA$-428.31K | -0.107x | -165.74% |
| 2020-10-31 | CA$4.86 Million | CA$-195.03K | -0.040x | -102.89% |
| 2019-10-31 | CA$-42.13K | CA$-58.55K | 1.390x | +398.33% |
| 2018-10-31 | CA$122.57K | CA$34.18K | 0.279x | +460.73% |
| 2017-10-31 | CA$120.97K | CA$-9.35K | -0.077x | +82.00% |
| 2016-10-31 | CA$384.43K | CA$-165.07K | -0.429x | +51.91% |
| 2015-10-31 | CA$506.89K | CA$-452.55K | -0.893x | -- |